JAK2 and osteosarcoma: It has been reported [134] that lymphocyte cytoplasmic protein 1 (LCP1) in BMSC-Exos promotes the progression of osteosarcoma through the JAK2/STAT3 pathway, suggesting that targeting LCP1 may provide a means to treat osteosarcoma.